A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer

British Journal of Cancer

Volumn 103, Issue 10, 2010, Pages 1536-1541

  Lopez R ^a   Salgado, M ^b   Reboredo, M ^c   Grande, C ^d   Mendez J C ^e   Jorge, M ^f   Romero, C ^g   Quintero, G ^b   De La Camara J ^h   Candamio, S ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Complejo Hospitalario de Ourense ^*  (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL DO MEIXOEIRO   (Spain)

^e Centro Oncologico de Galicia   (Spain)

^f HOSPITAL XERAL CÍES   (Spain)

^g Hospital Provisa   (Spain)

^h Universidad de La Coruña   (Spain)

Author keywords

bevacizumab; colorectal cancer; first line treatment; FOLFIRI

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; ALOPECIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLIC; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ESOPHAGITIS; FEMALE; HICCUP; HUMAN; HYPERTENSION; LIVER METASTASIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SPAIN; THROMBOPHLEBITIS; VOMITING; WOUND HEALING IMPAIRMENT;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG TOLERANCE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SAFETY; SPAIN; TREATMENT OUTCOME;

EID: 78149464410     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605938     Document Type: Article

References (26)

1. Cassidy J (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 16(12): 2006-2012
2. Diaz-Rubio E, Schmoll HJ (2005) The future development of bevacizumab in colorectal cancer. Oncology 69(Suppl 3): 34-45
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colo-rectal cancer: a multicentre randomised trial. Lancet 355(9209): 1041-1047
4. Falcone A, Loupakis F, Cupini S, Cortesi E, Buonadonna A, Tomasello G, Banzi M, Ronzoni M, Zaniboni G, Masi G (2010) FOLFIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol 28(Suppl): 15s, abstr 3543
5. Fortner BV (2007) Symptom burden for patients with metastatic colorectal cancer treated with first-line FOLFOX or FOLFIRI with and without bevacizumab in the community setting. Support Canther Ther 4(4): 233-240
6. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoro-pyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25(30): 4779-4786
7. Hochster HS (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 24(18s): 3510
8. Hurwitz H (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342
9. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23(15): 3502-3508
10. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1): 60-65
11. Kabbinavar F, Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Mass R, Perrou B, Nelson B, Novotny W (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16): 3697-3705
12. Kohne CH, Van CE, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Ruckle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Muller L, Genicot B, Anak O, Nordlinger B (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23(22): 4856-4865
13. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28(3): 453-459
14. López G, Pollán M, Pérez B (2004) Informe sobre la salud de los españoles. Cáncer. Información disponible a diciembre 2003. Madrid, Spain, Centro Nacional de Epidemiología. Instituto Nacional Carlos III: Madrid, Spain
15. Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 16(1): 301-308
16. Moehler M (2009) Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 15(4): 449-456
17. Omura K (2008) Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 77(Suppl 1): 13-22
18. Pectasides DG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papaxoinis G, Papakostas P, Bournakis E, Papandreou C, Fountzilas G (2010) Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/ fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). J Clin Oncol 28(Suppl): 15s, abstr 3541
19. Popov I (2008) The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy. Acta Chir Iugosl 55(4): 11-16
20. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20): 4593-4599
21. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13): 905-914
22. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22(18): 3766-3775
23. Tyagi P (2006) Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer 6(4): 261-264
24. WHO (2003) Human cancers by organ site; colorectal cancer. In World Cancer Report, Stewart BW, Kleihues P (eds), pp 198-202. IARC Press: Lyon, France
25. Willett CG, Boucher Y, di TE, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2): 145-147
26. Ziras N, Polyzos A, Xenidis N, Kalykaki A, Androulakis NE, Papakotoulas P, Kentepozidis NK, Makrantonakis P, Xynogalos S, Sougklakos I (2010) CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC). J Clin Oncol 28 (suppl; abstr 3542): 15s